Uniqure NV (QURE NASDAQ) stock market data APIs
$44.6384
0.15(0.3%)
as of September 11, 2026
Try our APIs with
free plan!
Uniqure NV Financial Data Overview
Price chart is built with
Anychart
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Prev. Close
44.6384
Open
44.7884
High
45.5741
Low
43.7126
52 wk Range
8.73-71.5
Market Cap
3 087 M
Shares Outstanding
69 366 K
Revenue
18 672 K
EPS
-1.22
Beta
0.944
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Uniqure NV (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Uniqure NV data using free add-ons & libraries
Get Uniqure NV Fundamental Data
Uniqure NV Fundamental data includes:
- Net Revenue: 18 672 K
- EBITDA: -182 916 000
- Earnings Per Share: -4
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-07-29
- EPS/Forecast: -0.81
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Uniqure NV News
New
Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?
A month has gone by since the last earnings report for Spyre Therapeutics (SYRE). Shares have lost about 16.6% in that time frame, underperforming the S&P 500. But investors have to be wondering, wil...
QURE Submits Application for Gene Therapy for Huntington's Disease
uniQure N.V. QURE announced that it has submitted a Biologics License Application ("BLA") to the FDA seeking accelerated approval for ifezuntirgene inilparvovec (AMT-130), an investigational gene ther...
UniQure's Embattled Huntington's Gene Therapy Clears A Key Hurdle
Uniqure stock wavered Wednesday after the Food and Drug Administration accepted its application for approval of a Huntington's gene therapy. Continue Reading
Sirius XM upgraded, Toast downgraded: Wall Street's top analyst calls
Sirius XM upgraded, Toast downgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls t...
Get Uniqure NV fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
